ERBB2 and breast cancer: For instance, the monoclonal antibodies such as trastuzumab and pertuzumab can effectively control the progression of both primary and metastatic HER2+ BC.[4] Despite these advances, metastatic HER2+ BC inevitably develops therapeutic resistance, resulting in disease progression.